Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiane Pott

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.
Cancer Research|August 24, 2012
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresAlba Navarro, Guillem Clot, Cristina Royo, et al.
Leukemia|November 3, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trialMouhamad Khouja, Elisa Genuardi, Simone Ferrero, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Leukemia|June 23, 2019
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGSHenrik Knecht, Tomas Reigl, Michaela Kotrová, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.
Cancer Research|August 24, 2012
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresAlba Navarro, Guillem Clot, Cristina Royo, et al.
Leukemia|November 3, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trialMouhamad Khouja, Elisa Genuardi, Simone Ferrero, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Leukemia|June 23, 2019
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGSHenrik Knecht, Tomas Reigl, Michaela Kotrová, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Pageof 12